Gene therapy available for all patients
Socially responsible pricing
We are here for the patient
LentiCure is publicly owned: full subsidiary of Erasmus MC Holding
Open and transparent
Society pays, so it has the right to information
We are committed to a future in which all rare genetic diseases can be treated with gene therapy at socially acceptable costs.
We are committed to a future in which all rare genetic diseases can be treated with gene therapy at socially acceptable costs.